AMPK alpha 1 CRISPR Activation Plasmid (h): sc-400104-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- AMPK alpha 1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- AMPK alpha 1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by AMPK alpha 1 CRISPR Activation Plasmid (h) and AMPK alpha 1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PRKAA1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: AMPK alpha 1 Antibody (H-4): sc-398861
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AMPK alpha 1 CRISPR Activation Plasmid (h) | sc-400104-ACT | 20 µg | $397.00 |
PRKAA1 encodes AMPK alpha 1, the catalytic subunit of the AMP-activated protein kinase complex that senses cellular energy status and coordinates adaptive metabolic responses. Upon activation, AMPK modulates glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and autophagy while restraining anabolic pathways, in part through crosstalk with mTORC1 and regulation of transcriptional programs. AMPK alpha 1 integrates signals from upstream kinases such as LKB1 and CaMKK2 to control cell growth, redox balance, and stress survival. Dysregulated AMPK signaling has been implicated in metabolic disorders, cancer cell metabolic reprogramming, and inflammatory phenotypes, making PRKAA1 a useful node for pathway-level interrogation.
AMPK alpha 1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PRKAA1 expression without altering the underlying DNA sequence.
AMPK alpha 1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PRKAA1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PRKAA1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous AMPK alpha 1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PRKAA1 locus and enabling the study of AMPK alpha 1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of AMPK alpha 1 pathway restoration in tumor cells with silenced or reduced PRKAA1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.